Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-23T18:02:48.066Z Has data issue: false hasContentIssue false
  • English
  • Français

Preliminary results of CyberKnife stereotactic radiotherapy (SBRT) boost for primary head and neck cancers: is it the future direction?

Published online by Cambridge University Press:  14 January 2015

Tejinder Kataria ,
Trinanjan Basu ,
Shikha Goyal ,
Ashu Abhishek ,
Deepak Gupta ,
Vikraman Subramani ,
K. P. Karrthick  and
Shyam S. Bisht
Tejinder Kataria
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
Trinanjan Basu*
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
Shikha Goyal
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
Ashu Abhishek
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
Deepak Gupta
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
Vikraman Subramani
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
K. P. Karrthick
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
Shyam S. Bisht
Affiliation:
Division of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, India
*
Correspondence to: Trinanjan Basu, Division of Radiation Oncology, Medanta The Medicity, Gurgaon, India. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim

To analyse the preliminary results of CyberKnife stereotactic radiotherapy (SBRT) boost in primary head and neck cancer patients among Indian population.

Methods and materials

A total of nine patients of primary head and neck cancer were treated with CyberKnife SBRT boost after intensity-modulated radiation therapy (IMRT). The median phase 1 IMRT dose was 54 Gy/27 fractions. Histological types included squamous cell carcinoma (n=7) and adenoid cystic carcinoma (n=2). Response was evaluated using positron emission tomography/computed tomography and detailed clinical examination.

Results

As a preliminary analysis with median follow up of 8 months (range: 6–19 months), phase 2 median tumour volume of 16·3 cc and a median dose of 5 Gy per fraction, eight patients had loco-regionally stable disease and one had distant metastasis. With objective assessment five patients had complete response. Treatment was well tolerated with no grade 3 or more acute toxicities directly related to CyberKnife boost.

Conclusion

CyberKnife SBRT boost is an attractive option for primary head and neck cancers especially where disease is in close proximity to critical structures hindering radical dose delivery. Future prospective analysis and optimum assessment of total biological effective dose (BED) in a properly selected case might actually benefit the use of CyberKnife SBRT boost.

Keywords

CyberKnifeCyberKnife boosthead and neck cancerIMRT
Type
Original Articles
Information
Journal of Radiotherapy in Practice , Volume 14 , Issue 2 , June 2015 , pp. 187 - 193
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Bernier, J, Domenge, C, Ozsahin, Met al.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945–1952.CrossRefGoogle ScholarPubMed
2.Cooper, J S, Pajak, T F, Forastiere, A Aet al.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937–1944.CrossRefGoogle ScholarPubMed
3.Bonner, J A, Harari, P M, Giralt, Jet al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–578.CrossRefGoogle ScholarPubMed
4.Adler, J R Jr, Murphy, M J, Chang, S D, Hancock, S L.Image-guided robotic radiosurgery. Neurosurgery 1999; 44: 1299–1306.Google Scholar
5.Chang, S D, Adler, J R. Robotics and radiosurgery – the cyberknife. Stereotact Funct Neurosurg 2001; 76: 204–208.CrossRefGoogle ScholarPubMed
6.Eisenhauer, E A, Therasse, P, Bogaerts, Jet al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1). Eur J Cancer 2009; 45: 228–247.Google Scholar
7.Bachar, G Y, Goh, C, Goldstein, D P, O’Sullivan, B, Irish, J C. Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur Arch Otorhinolaryngol 2010; 267: 295–301.CrossRefGoogle ScholarPubMed
8.Argiris, A, Ghebremichael, M, Gilbert, Jet al.Phase III randomized, placebo controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013; 31: 1405–1414.Google Scholar
9.Soulieres, D, Senzer, N N, Vokes, E E, Hidalgo, M, Agarwala, S S, Siu, L L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77–85.CrossRefGoogle ScholarPubMed
10.Siddiqui, F, Patel, M, Khan, Met al.Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009; 74: 1047–1053.Google Scholar
11.Cacicedo, J, Navarro, A, Alongi, Fet al.The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. Cancer Treatment Rev 2014; 40: 178–189.Google Scholar
12.Fuks, Z, Kolesnick, R. Engaging the vascular component of the tumor response. Cancer Cell 2005; 8: 89–91.Google Scholar
13.Roh, K W, Jang, J S, Kim, M Set al.Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1348–1355.Google Scholar
14.Le, Q T, Tate, D, Koong, Aet al.Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 1046–1054.Google Scholar
15.Uno, T, Isobe, K, Ueno, Net al.Fractionated stereotactic radiotherapy as a boost treatment for tumors in the head and neck region. J Radiat Res 2010; 51: 449–454.CrossRefGoogle ScholarPubMed
16.Vargo, J A, Ferris, R L, Clump, D A, Heron, D E. Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer. Front Oncol 2014; 11 (4): 214.CrossRefGoogle Scholar